The cash runway of $5.6M at current burn rate (~$3.3M/quarter operating expenses) provides less than 2 quarters of liquidity, making a dilutive equity financing or partnership deal for PDS0101 highly probable in the near term. The Phase 3 discontinuation removes a key catalyst; PDS0301 data is early-stage (Phase 2 mCRC, n=9). Traders should watch for financing announcements and PDS0301 partnership or clinical updates.
Drugs in focus
PDSB drug pipeline →PDS0301
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
- Next catalyst
- None dated
What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 13 $0.2332entry
- T+1 · 3mo ago −1.11%α −0.92% · $0.2306
- T+5 · 3mo ago −10.42%α −8.46% · $0.2089
- T+20 · 2mo ago +26.46%α +28.20% · $0.2949
- T+60 · 11d ago +427.44%α +432.92% · $1.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a strategic refocus to prioritize PDS0301, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101. Cash burned to $5.6M from $21.7M at year-end, with negative working capital of -$5.3M, raising going-concern risk. The pipeline pivot and cash runway depletion are the primary stock-moving events, outweighing the earnings miss for this pre-revenue biotech.
Key Financial Metrics
Key Facts
- Net loss of $9.8M ($0.18/share) for Q2 2026 vs $9.4M ($0.21/share) in Q2 2025
- EPS of -$0.18 missed consensus of -$0.13 by 42.1%
- Cash balance fell to $5.6M as of June 30, 2026, from $21.7M at March 31, 2026
- Working capital turned negative to -$5.3M from positive $18.8M at year-end 2025
- Company ceased internal investment in PDS0101, discontinuing VERSATILE-003 Phase 3 trial
- Strategic refocus prioritizes PDS0301 (formerly PDS01ADC) as lead development program
- Long-term debt retired to $0 from $11.7M at year-end 2025
- Total stockholders' equity negative at -$3.6M vs positive $9.3M at year-end 2025
Financial Impact
Cash burn of ~$16.1M in H1 2026; $5.6M remaining cash likely insufficient for more than one quarter of operations without financing
Risk Factors
- Cash runway insufficient to fund operations beyond Q4 2026 without additional capital
- Discontinuation of VERSATILE-003 Phase 3 trial eliminates near-term regulatory catalyst for PDS0101
- PDS0301 is early-stage (Phase 2, single-center, n=9) with no confirmed regulatory pathway
- Negative stockholders' equity (-$3.6M) and working capital deficit (-$5.3M) signal financial distress
- Potential Nasdaq delisting risk if stock price remains below $1.00
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032650 |
| Document: ef20080122_8k.htm | 0001140361-26-032650 |
| Document: 0001140361-26-032650-index-headers.html | 0001140361-26-032650 |
| Document: 0001140361-26-032650-index.html | 0001140361-26-032650 |
| Document: 0001140361-26-032650.txt | 0001140361-26-032650 |
| 8-K Data (Synthetic) | 0001140361-26-032650 |
Track record
28 reports on PDSB
7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers